Hosted on MSN
Novo Nordisk and Hims & Hers Health resolve patent dispute and collaborate on weight loss medications
Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...
Hosted on MSN
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny
Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity ...
Reuters
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
May 21 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab said on Thursday it is now offering Canadians a generic version of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO), opens ...
MobiHealthNews
Hims & Hers launches generic semaglutide offering in Canada
Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...
Seeking Alpha
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims
News broke yesterday that the FDA is proposing to exclude the globally best-selling prescription drug molecules semaglutide, tirzepatide and liraglutide from its 503B bulk list, "finding no clinical ...